{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.3651","statisticalMethod":"Cochran-Mantel-Haenszel","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.00","value":"0.41"},{"groupId":"OG001","spread":"0.00","value":"0.00"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"5"}],"units":"Participants"}],"description":"Total number of bleeding events (Grade 2 or higher, i.e., mild to life-threatening, as defined in the protocol) for each participant during Weeks 2-13 (end-of-study visit for non-responders)","dispersionType":"Standard Deviation","groups":[{"description":"Romiplostim by subcutaneous injection once weekly at a starting dose of 1 µg/kg, adjusted based on weekly platelet counts to a maximum weekly dose of 10 µg/kg","id":"OG000","title":"Romiplostim"},{"description":"Placebo by subcutaneous injection once weekly","id":"OG001","title":"Placebo"}],"paramType":"MEAN","populationDescription":"Efficacy Analysis Set, composed of all randomized participants","reportingStatus":"POSTED","timeFrame":"12-week treatment period (Weeks 2 - 13)","title":"Bleeding Events (Grade 2 or Higher)","type":"SECONDARY","unitOfMeasure":"Events per participant"}